796870-83-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 37033-95-7 5-benzyloxy-1H-indole-2-carboxylic acid ethyl ester 

Downstream Products

• 1093256-36-0 3-bromo-N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-5-[(2-hydroxyethyl)oxy]-1H-indole-2-carboxamide 
• 1093256-35-9 N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-5-{[3-(methylthio)propyl]oxy}-1H-indole-2-carboxamide 
• 1093256-33-7 N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-2,3-dihydro-7H-[1,4]oxathiino[3,2-e]indole-8-carboxamide 
• 1093256-32-6 N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-5-{[2-(methylthio)ethyl]oxy}-1H-indole-2-carboxamide 
• 1093255-64-1 N-({4-chloro-3-[(3-chloro-5-cyanophenyl)oxy]-2-fluorophenyl}methyl)-5-{[(3S)-3,4-dihydroxybutyl]oxy}-1H-indole-2-carboxamide 
• 1093631-42-5 5-[4-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)phenyl]-1H-indole-2-carboxylic acid 
• 1093631-65-2 1-(1,1-dimethylethyl) 2-ethyl 5-(4-hydroxyphenyl)-1H-indole-1,2-dicarboxylate 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The present invention relates to compounds that are a non-nucleoside reverse transcriptase inhibitors, and to processes for the preparation and use of the same. Specifically, the present invention includes methods of using such compounds in the treatment of human immunodeficiency virus infection.

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1 H4) FXR is a member of the nuclear receptor class of ligand-activated transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceu

CBI analogues of the duocarmycins and CC-1065

An extensive series of CBI analogues of the duocarmycins and CC-1065 exploring substituent effects within the first indole DNA binding subunit is detailed. In general, substitution at the indole C5 position led to cytotoxic potency enhancements that can be ≧1000-fold providing simplified analogues containing a single DNA binding subunit that are more potent (IC50=2-3 pM) than CBI-TMI, duocarmycin SA, or CC-1065. The increases in cytotoxicity correlate well with accompanying increases in the rate and efficiency of DNA alkylation. This effect is more pronounced with the CBI versus DSA or CPI based analogues. Moreover, this effect is largely insensitive to the electronic character of the C5 substituent but is sensitive to the size, rigid length, and shape (sp, sp2, sp3 hybridization) of this substituent consistent with expectation that the impact is due simply to its presence.